STAAR Surgical Sales Double to $93.5 Million on China Demand

STAAR Surgical Co (NASDAQ: STAA) reported second-quarter fiscal 2026 net sales of $93.5 million, up 111% year over year, driven by China demand for its EVO Plus implantable lens while the company works through supply constraints and tariff costs.

STAAR Surgical Co (NASDAQ: STAA) told investors its second-quarter fiscal 2026 net sales rose 111% from a year earlier to $93.5 million, a figure the company attributed chiefly to strong Chinese demand for EVO Plus, its newer implantable collamer lens. The eye-implant maker also flagged two constraints running against the top line: limits on what it can supply, and tariff costs it has to absorb or pass on.

The shares closed at $25.41 on Wednesday, up 1.88% from the prior close of $24.94, having traded between $24.68 and $26.03 during the session. Broader benchmarks were mixed-to-firm the same day, with the S&P 500 tracker at $772.49 (+0.25%) and the Nasdaq 100 tracker at $723.70 (+0.73%).

Why a 111% jump says as much about last year as this one

A doubling of sales is arresting, but the arithmetic of percentage growth depends entirely on what it is measured against. STAAR's China business went through a severe inventory correction — distributors in the market had ordered ahead of demand, and the company spent quarters shipping less than end-patients consumed while that excess worked down. When a comparable quarter is depressed by destocking, the following year's growth rate flatters the underlying trend.

That does not make the $93.5 million meaningless. The absolute number is the thing to anchor on, because it reflects orders actually placed rather than a ratio against a weak base. What the growth rate does not tell an investor is how much of the quarter represents distributors rebuilding shelf stock versus surgeons implanting more lenses. Those two things look identical on an income statement and behave very differently in the quarter after.

The GuruFocus account of the earnings call frames the quarter as a record revenue surge alongside strategic growth, with management working through market challenges. The challenges named — supply and tariffs — are the ones that decide whether the run rate holds.

Supply constraints cut both ways for a single-product story

Being unable to make enough of something is a better problem than being unable to sell it, but it is still a problem. For a company whose growth is concentrated in one product family in one large market, a supply ceiling does three things at once.

It caps upside in the quarter, regardless of how strong ordering is.
It obscures true demand, because shipments become a function of capacity rather than appetite.
It invites distributors to over-order defensively, which is exactly the behavior that produced the destocking cycle in the first place.

The last point is the one worth watching most closely. A manufacturer that is short of product often finds its channel partners padding orders to secure allocation. That inflates near-term revenue and plants the seeds of the next correction. Investors reading future quarters should look for management commentary on channel inventory levels and on end-market implant volumes, not just on shipped sales.

Tariffs land on a cross-border manufacturing chain

Tariff headwinds are a margin story rather than a revenue one, at least initially. A medical device that is manufactured in one jurisdiction and implanted in another crosses borders as a physical good, and duties attach to that crossing. The company can eat the cost, raise prices, reroute production, or renegotiate with distributors — and each option has a cost that shows up somewhere in the accounts.

Raising prices in an elective-surgery market is not trivial. Refractive lens implantation competes with laser vision correction and with the option of simply continuing to wear glasses. Consumers paying out of pocket are sensitive to price in a way that patients covered by insurance are not. That limits how much of a tariff bill can be pushed downstream in China, which is precisely where the growth is coming from.

Concentration risk is the through-line

Every element of this quarter routes back to a single geography. China drove the growth, China is where the destocking happened, and China is where tariff and trade policy risk is most acute for an American manufacturer. Diversification of revenue is the structural fix, and it takes years — regulatory clearances, surgeon training, distributor networks, reimbursement pathways in markets where such pathways exist.

For the stock, that concentration is why the reaction to a doubling of sales was measured rather than euphoric. A 1.88% close-to-close gain on a quarter with a triple-digit growth headline suggests the market had already discounted a recovery in Chinese ordering and was reading the release for the durability of it. Shares finished nearer the middle of the day's $24.68–$26.03 band than at its top.

What the next two quarters have to prove

Three specific things would turn this quarter from a rebound into a trend.

Sequential stability. If quarterly sales hold near this level once the year-ago comparison stops being easy, the demand is real. If they sag, the quarter was a restock.
Capacity coming online. Supply constraints named on a call are usually being addressed. Evidence of added output would remove the ceiling and let reported sales track demand again.
Gross margin. This is where tariffs, freight and any price concessions to distributors will surface. Revenue growth with compressing margin is a lower-quality outcome than slower growth at a stable one.

Beyond that, the geographic mix line in future filings matters more than the headline growth rate. Any meaningful contribution from markets outside China would reduce the single-country dependency that currently defines the investment case, in either direction.

How the setup looks against the tape

STAAR is a small-capitalization medical device name reporting into an equity market that closed higher on the day, with the technology-heavy Nasdaq 100 tracker outperforming the broad market at +0.73% against +0.25% for the S&P 500 proxy. The Dow tracker was essentially flat at $537.15, down 0.02%. That backdrop is neither a tailwind nor an obstacle for a company whose fortunes rest on Chinese refractive-surgery volumes and on duty rates set by policymakers.

The bull case is straightforward: a product with clear clinical appeal, a large addressable population of myopic patients in Asia, and a channel that has finished purging excess inventory. The bear case is equally clean: one product, one dominant market, a manufacturing chain exposed to trade policy, and a sales line that has already demonstrated it can swing violently in both directions. This quarter argued the bull case. The next two will be the test of it.

Key facts

Q2 FY2026 net sales: $93.5 million, up 111% year over year
Growth driver: China demand for EVO Plus implantable lens
STAA last close: $25.41, +1.88% (as of 20:00 GMT, 12 Aug 2026)
Headwinds cited: Supply constraints and tariffs

Frequently asked questions

How much did STAAR Surgical's second-quarter sales grow?

STAAR Surgical reported second-quarter fiscal 2026 net sales of $93.5 million, an increase of 111% from the same quarter a year earlier. The company credited robust demand in China for its EVO Plus implantable collamer lens as the main driver of the increase, while noting supply constraints and tariff pressures during the period.

Why did the sales figure more than double?

Two forces were at work. Demand in China for EVO Plus was strong, and the year-earlier comparison period was depressed because distributors were working down excess inventory. When a base quarter is weakened by destocking, the following year's percentage growth looks larger than the underlying trend in surgical volumes.

What is EVO Plus?

EVO Plus is part of STAAR Surgical's family of implantable collamer lenses, devices placed inside the eye to correct myopia as an alternative to laser vision correction or glasses. It is the product the company identified as driving the second-quarter revenue increase, with Chinese demand cited specifically on the earnings call.

How do tariffs affect STAAR Surgical?

Tariffs are primarily a margin issue rather than a revenue one. Because the lenses cross borders as physical goods, duties attach at import. The company can absorb the cost, raise prices, or shift production, and each option carries a cost. Raising prices is difficult in an elective, largely out-of-pocket surgery market.

Where did STAA shares close?

STAAR Surgical stock closed at $25.41, a gain of 1.88% from the previous close of $24.94, with a session range of $24.68 to $26.03, as of 20:00 GMT on 12 August 2026. That was a modest reaction relative to the size of the reported revenue increase.

What should investors watch in the next quarters?

Three things: whether quarterly sales hold near this level once the easy year-ago comparison passes, whether supply capacity expands enough to lift the shipment ceiling, and how gross margin holds up against tariff and freight costs. Geographic revenue mix also matters, given how concentrated the business is in China.

Sources

Staar Surgical Co (STAA) (Q2 2026) Earnings Call Highlights: Record Revenue Surge and Strategic ... — GuruFocus

Photo: Anna Shvets · Pexels Licence — source